Review

Interacting Models of Amyloid-β and Tau Proteins: An Approach to Identify Drug Targets in Alzheimer’s Disease

Priya Khadgawat, J.M. Siddesha, Dharini Shashank and Shashanka K. Prasad,∗

a Department of Genetics, University of Delhi, New Delhi, India
b Division of Biochemistry, Faculty of Life Sciences, JSS Academy of Higher Education and Research (JSSAHER), Mysuru, Karnataka, India
c Department of Burns, Plastic and Maxillofacial Surgery, VMMC and Safdarjung Hospital, New Delhi, India
d Department of Biotechnology and Bioinformatics, Faculty of Life Sciences, JSS Academy of Higher Education and Research (JSSAHER), Mysuru, Karnataka, India

Accepted 14 April 2021
Pre-press 11 May 2021

Abstract. Alzheimer’s disease (AD) is the primary cause of dementia affecting millions each year across the world, though still remains incurable. This might be attributed to the lack of knowledge about the associated proteins, their cellular and molecular mechanisms, and the genesis of the disease. The discovery of drugs that earlier revolved around targeting the amyloid-β cascade has now been reformed with the upgraded knowledge of the cross-seeding ability of tau protein which opens new gateways for therapeutic targets. This article provides a comprehensive review of various direct and indirect connecting pathways between the two main proteins involved in development and progression of AD, enabling us to further expand our repertoire of information regarding the etiology of AD. The current review indicates the need for extensive research in this niche, thus considerable advances can be made in understanding AD which eventually helps to improve the current therapeutics against AD.

Keywords: AGE, Alzheimer’s disease, CDK5, GSK3, oxidative stress, RAGE

INTRODUCTION

Alzheimer’s disease, named after its discoverer Dr. Alois Alzheimer, is a neurodegenerative disorder characterized by the formation of extracellular insoluble plaques of amyloid-β (Aβ) protein and intraneuronal tangles of tau protein (τP) developed in the neuronal cells [1]. Amyloid-β protein precursor (AβPP) is a transmembrane protein of neurons which is involved in the growth and repair mechanism [2]. These proteins are cleaved by two enzymes, α-secretase and γ-secretase, producing a soluble peptide which will be degraded; however, in the presence of another enzyme, β-secretase, along with γ-secretase, it produces an insoluble sticky Aβ monomer which aggregates outside neuronal cells [3, 4]. The plaques formed are localized between synapses disrupting signals and further
neuronal cells. On the other hand, some studies have revealed the role of tau, in order to reduce the rate of deterioration of proteins, the role it plays in inducing phosphorylation plaques to the interaction between the two proteins [19]. However, the strength of association to Aβ protein is dictated by the nature of τP, i.e., whether it is in phosphorylated or dephosphorylated form [24]. The phosphorylation of serine and threonine amino acid residues of τP has been shown to decrease its affinity toward Aβ protein, with the help of techniques such as Enzyme linked immunosorbent assay and western blotting [25]. This dependency indicated the direct role of Aβ in the phosphorylation of τP proteins, and alongside, in vivo demonstration of the co-localization of proteins was displayed by immunofluorescence assay [25].

Moreover, the researchers were able to discover the interactive sites on these proteins by utilizing peptide membrane arrays, exons 7 and 9 of τP, and middle to C-terminal region of Aβ were discovered to be the interacting sites [25]. This common interactive site occurs to be exploited in identifying a therapeutic drug target to reduce prion aggregation [26].

**INDIRECT INTERACTIVE MODELS**

Here presented are the brief outlines of various models describing the indirect interactions between Aβ and τP proteins that invariably occur through cell signaling pathways.

**GSK3: One of the culprits**

Glycogen synthase kinase 3 (GSK3) phosphorylates tau protein [27], which causes its detachment from microtubules and then their aggregation. The Aβ plaques hinder both insulin [28] and Wnt signaling pathways [29], creating an abundance of activated GSK3 in the neuronal cells. In the insulin pathway, Aβ acts as an antagonist to insulin, inhibiting phosphoinositide 3-kinase (PI3), and Akt (serine/threonine-specific protein kinase) activation, as shown in Fig. 1. Akt kinase phosphorylates two
isoforms of GSK3, i.e., GSK3α and GSK3β, causing it to lose its kinase property and to be able to phosphorylate τP. However, if Akt is inhibited, the GSK3 is not phosphorylated and is available with its active phosphorylating property [28].

The Wnt pathway in one of its parts is responsible for the inactivation of GSK3; on the other hand, the presence of Aβ protein does not allow it to do that, and hence activated GSK3 peptides are present in the neuronal cells. The above-stated deviations of the cellular mechanisms are known to occur in familial AD [30].

**CDK5: Another culprit**

Cyclin-dependent kinase 5 (CDK5), a known kinase of tau protein, structurally similar to another kinase GSK3, is involved in regulating the cell cycle and several different cellular mechanisms in neurons [31]. The p35 and p39 forms are the activators of CDK5, which are involved in the proteasome degradation of CDK5, upon phosphorylation [32]; however, it gets cleaved into more stable p25 and p29 by calcium-dependent protease calpain. It was activated in presence of a high concentration of Ca$^{2+}$ ions in the cell, an outcome of Aβ toxicity [33]. Hence, in the presence of stable activators, CDK5 remains active for a prolonged time in the cell causing phosphorylation of τP proteins [33] as shown in Fig. 2.

Protein phosphatases 1 and 2A are the main dephosphorylating agents of tau protein [34]. Protein phosphatases 1 is involved in activating GSK3β [35] and protein phosphatases 2A dephosphorylates Akt and thus inhibiting its activity [36]. The p25 has been shown to have a higher affinity toward GSK3β than CDK5, and therefore it binds to its C-terminus domain, causing an alternation in its activity, leading to an increase in phosphorylation of tau proteins [37].

**Oxidative stress-mediated tau phosphorylation**

Aβ oligomers interact with the neuronal membrane through receptors such as N-methyl-D-aspartate receptor (NMDAR), Ephrin type-A receptor 4 precursor [38], cellular prion protein [39], or can even get embedded into the lipid bilayer, leading to peroxidation of bilayer molecules that causing the damage to proteins, and hence taking our prime defense down [40].

Inside the cell, Aβ can induce tau phosphorylation through a plethora of pathways, for some of them the working mechanism is known (Fig. 3):

- **AGE-RAGE Stress** [41] - Advanced glycation end products (AGE) and its receptor (RAGE) play a role in the etiology of AD. RAGE is a multi-ligand, and once Aβ transacts, it induces activation of Nuclear factor Kappa B (NF-κB), which further upregulates the level of various cytokines in the cell, and thus cause cell death [42]. Its activation also increases the expression of RAGE and makes cells more prone to external stress [42]. Their transact also activates NADPH oxidase [43], which leads to an increase in the
concentration of reactive oxygen species (ROS) [44]. Cytokines are also known to upregulate this oxidase [45]. ROS further increases the production of Aβ oligomers [46].

- Aβ hinders the activity of both complex I and IV of the electron transport chain [47] in mitochondria, by directly associating with subunit 1 of cytochrome c oxidase, the major site for the production of ROS and hence causing its upregulation in the cell [40].
- Aβ induces higher expression of Regulator of calcineurin gene (RCAN1) through oxidative stress as it responds to it [48], which further inhibits the phosphatase activity of calcineurin, an enzyme that dephosphorylates tau protein. It also increases levels of GSK3β, a kinase known to phosphorylate tau [49].
- The presence of Aβ has also been shown to decrease the levels of superoxide dismutase 2 (SOD2), which provide protection against the production of ROS, especially superoxides, and such a downregulation leads to their accumulation and increases in phosphorylation of τP. A plausible explanation can be due to the depletion of microtubule dependent protein 2 (MAP2), a protein required for the association of tau with microtubules, whose reduction has been linked to hyperphosphorylation of tau [50].

**Acetylation of tau: associate of phosphorylation**

Tau protein, similar to any other protein, can undergo various post-translational modifications including phosphorylation, acetylation [51], nitration [52], glycation [53], etc.

Aβ oligomers have been shown to induce nitric oxide (NO) production, nitrosylated glyceraldehyde 3-phosphate dehydrogenase (GAPDH) which acetylates p300 acetyltransferase, causing its activation and then acetylation of tau protein [54] as shown in Fig. 4. Nitrosylated GAPDH causes deactivation by nitrosylation of Sirtuin1 (SIRT1), a deacetylase of tau, further increasing the possibility of tau
Fig. 4. A Schematic representation of how Aβ dictates tau phosphorylation via a GAPDH nitrosylated dictated pathway which acetylates p300 and nitrosylates SIRT1 promoting tau acetylation which furthermore causes its phosphorylation by PDKs [55].

Fig. 5. A schematic representation of tau influenced Aβ toxicity by enhancing the sensitivity of NMDAR receptor to Aβ peptides through its phosphorylation by FYN kinase [58].

acetylation [55]. Its acetylation sets off its aggregation through phosphorylation by proline-directed protein kinases (PDPKs) [56].

Dendritic tau-dependent Aβ toxicity

Tau protein, abundantly seen in axon and comparatively less in dendrites [57], upon phosphorylation, detaches from the microtubule and forms intracellular neurofibrillary tangles. These tangles of tau protein show greater affinity towards FYN, a tyrosine-protein kinase that is then localized to the somatodendritic region, further to phosphorylate NMDAR receptor present in the neuronal membrane and facilitates its interaction with postsynaptic density protein (PSD95) [58] (Fig. 5). Once NMDAR receptors are phosphorylated, they become more sensitive to the already existing Aβ plaques, which induce further downstream toxicity effects [22], and it also induces an influx of Ca^{2+} ions and affects other pathways, ultimately leading to neuronal loss [59].

CONCLUSIONS

The interacting models of Aβ and rP stated in this review show the diverse signaling pathways that are involved in the etiology of AD, revealing the potential drug targets for the prevention or cure of the disease. Apart, there is a need to discover the other AD-associated pathways for a better understanding of the disease.

Earlier drugs used targeted the degradation of Aβ aggregates and failed to provide the desired outcome due to the seeding phenomena associated with the prion-like proteins. Nevertheless, the already phosphorylated tau proteins are sufficient to spread and cause toxicity to the cellular systems. The same situation persisted when rP tangles were targeted. Hence, aiming at only one of the proteins might not provide a cure to AD.

One current study that targets a common epitope involved in cross-seeding of the proteins with
peptide-based inhibitors has shown effective results in blocking the pathological forms of Aβ and τP [26]. However, better inhibitors could be used for effective and prolonged inhibition of protein aggregations.

Designing a drug that helps cure AD or at least control its progression would require a complete understanding of the crosstalk between Aβ and τP, molecular mechanisms of other associated signaling cascade proteins, taking into account the pharmacodynamics and pharmacokinetics of the drug. The application of nanotechnology toward the bioavailability of drugs and enhancing its qualities and reducing any downstream toxicity can also be utilized.

ACKNOWLEDGMENTS

PK is thankful to the organizers of the Virtual Internship with Science Leader (#VISL), outcome which is this review article. SJM and SKP thank JSS Academy of Higher Education and Research (JSSAHER), Mysuru, Karnataka, India, for the infrastructure and support provided.

CONFLICT OF INTEREST

The authors have no conflict of interest to report.

REFERENCES

[1] Alzheimer A (1911) Über eigenartige Krankheitsfälle des späteren Alters (On certain peculiar diseases of old age) - Translated and with an introduction by H Förstl and R Levy. Zbl Ges Neurol Psych 2, 71-73.
[2] Grimm MOW, Mett J, Grimm HS, Hartmann T (2017) App function and lipids: A bidirectional link. Front Mol Neurosci 10, 63.
[3] Selkoe DJ (2001) Alzheimer’s disease: Genes, proteins, and therapy. Physiol Rev 81, 741-766.
[4] Chen GF, Xu TH, Yan Y, Zhou YR, Jiang Y, Melcher K, Xu HE (2017) Amyloid beta: Structure, biology and structure-based therapeutic development. Acta Pharmacol Sin 38, 1205-1235.
[5] Nitsch RM, Blusztajn JK, Pittas AG, Slack BE, Growdon JH, Wurtman RJ (1992) Evidence for a membrane defect in Alzheimer disease brain. Proc Natl Acad Sci U S A 89, 1671-1675.
[6] Reiss AB, Arain HA, Stecker MM, Siegart NM, Kasselman LJ (2018) Amyloid toxicity in Alzheimer’s disease. Rev Neurol 29, 613-627.
[7] Goedert M, Spillantini MG, Cairns NJ, Crowther RA (1992) Tau proteins of Alzheimer paired helical filaments: Abnormal phosphorylation of all six brain isoforms. Neuron 8, 159-168.
[8] Vinters HV (2015) Emerging concepts in Alzheimer’s disease. Ann Rev Pathol Mech Dis 10, 291-319.
[9] Graham WV, Bonito-Oliva A, Sakmar TP (2017) Update on Alzheimer’s disease therapy and prevention strategies. Annu Rev Med 68, 413-430.
[10] Dickson DW (2004) Apoptotic mechanisms in Alzheimer neurofibrillary degeneration: Cause or effect? J Clin Invest 114, 23-27.
[11] Merriam AE, Aronson MK, Gaston P, Wey S-L, Katz I (1988) The psychiatric symptoms of Alzheimer’s disease. J Am Geriatr Soc 36, 7-12.
[12] Bature F, Guinn BA, Pang D, Pappas Y (2017) Signs and symptoms preceding the diagnosis of Alzheimer’s disease: A systematic scoping review of literature from 1937 to 2016. BMJ Open 7, e015746.
[13] Piaceri I, Nacmias B, Sorbi S (2013) Genetics of familial and sporadic Alzheimer’s disease. Front Biosci (Elite Ed) 5, 167-177.
[14] Tiwari S, Atluri V, Kaushik A, Yndart A, Nair M (2019) Alzheimer’s disease: Pathogenesis, diagnostics, and therapeutics. Int J Nanomedicine 14, 5541-5554.
[15] Avramopoulos D (2009) Genetics of Alzheimer’s disease: Recent advances. Genome Med 1, 34.
[16] Singh PP, Singh M, Mastana SS (2006) APOE distribution in world populations with new data from India and the UK. Ann Hum Biol 33, 279-308.
[17] Shen J, Kelleher RJ (2007) The presenilin hypothesis of Alzheimer’s disease: Evidence for a loss-of-function pathogenic mechanism. Proc Natl Acad Sci U S A 104, 403-409.
[18] Holtzman DM, Morris JC, Goate AM (2011) Alzheimer’s disease: The challenge of the second century. Sci Transl Med 3, 77sr1.
[19] Bloom GS (2014) Amyloid-β and tau: The trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol 71, 505-508.
[20] Alvarez G, Muñoz-Montaño JR, Satrustegui J, Avila J, Bogómez E, Díaz-Nido J (1999) Lithium protects cultured neurons against β-amyloid-induced neurodegeneration. FEBs Lett 453, 260-264.
[21] Busciglio J, Lorenzo A, Yeh J, Yanker BA (1995) β-Amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron 14, 879-888.
[22] Ittner LM, Ke YD, Delerue F, Bi M, Gladding S, van Eersel J, Wolling H, Chiang BC, Christie MJ, Napier IA, Eckert A, Auffenbiel M, Hardeman E, Götze J (2010) Dendritric function of tau mediates amyloid-β toxicity in Alzheimer’s disease mouse models. Cell 142, 387-397.
[23] Soto C, Pritzekow S (2018) Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases. Nat Neurosci 21, 1332-1340.
[24] Lasagna-Reeves CA, Castillo-Carranza DL, Guerrero-Bobán E, Díaz-Nido J (1999) Lithium protects cultured neurons against β-amyloid-induced neurodegeneration. Acta Pharmacol Sin 20, 291-302.
[25] Guo JP, Arai T, Miklossy J, McGeer PL (2006) Aβ and tau form soluble complexes that may promote self aggregation of both into the insoluble forms in Alzheimer’s disease. J Biol Chem 282, 33305-33312.
AGE-RAGE stress, stressors, and antistressors in health and disease.

Mora A, Sabio G, Risco AM, Cuenda A, Alonso JC, Soler Hernández F, Langa E, Cuadros R, Avila J, Villanueva N, Prasad K, Mishra M (2018) AGE-RAGE stress, stressors, and antistressors in health and disease. Mol Cell Biochem 459, 95-112.

Bobba A, Amadoro G, Valentí D, Corsetti V, Lassandro R, Atlante A (2013) Mitochondrial respiratory chain Complexes I and IV are impaired by β-amylod via direct interaction and through Complex 1-dependent ROS production, respectively. Mitochondrion 13, 298-311.

Cyclin dependent kinase 5 (Cdk5)

Hernández F, Gómez de Barreda E, Fuster-Matanzo A, Magdesian MH, Carvalho MMVF, Mendes FA, Saraiva M, Kerokoski P, Suuronen T, Salminen A, Soininen H, Pirttilä Peterson DW, Ando DM, Taketa DA, Zhou H, Dahlquist FW, Lew J (2010) Regulation of GSK3 isoforms by phosphatases PP1 and PP2A. Proc Natl Acad Sci USA 107, 2884-2889.

GSK3 and antistressors in health and disease.

Ip NY, Tsai LH (2008) Cyclin dependent kinase 5 (Cdk5). Springer-Verlag US.

Peterson DW, Ando DM, Taketa DA, Zhou H, Dahlquist FW, Lew J (2010) No difference in kinetics of tau or histone phosphorylation by CDK5/p25 versus CDK5/p35 in vitro. Proc Natl Acad Sci USA 107, 2884-2889.